drugset / Trial / NCT03206749

A Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy

NCT03206749

Phase 2 Completed 243 enrolled Vertex Pharmaceuticals Incorporated
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 2 randomized, double-blind, placebo-controlled, 3-arm, parallel design study to evaluate the efficacy and safety of VX-150 in treating acute pain following bunionectomy.

Timeline

Start
2017-06-29
Primary completion
2017-12-01
Completion
2017-12-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Acetaminophen Small molecule 325 mg
Subject VX-150 Unknown 750 mg
Comparator hydrocodone bitartrate Unknown 5 mg

Indications

No indication recorded.